Patents Assigned to CLERA INC.
  • Compositions and methods for treating parkinson's disease
    Patent number: 9192605
    Abstract: This application describes compositions of receptor inhibitors, including typical antipsychotic agents, for example haloperidol, and methods of use for treating clinical signs or symptoms of Parkinson's disease. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in Parkinson's disease as a means of alleviating the clinical signs or symptoms of Parkinson's disease.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: November 24, 2015
    Assignee: CLERA INC.
    Inventor: Philip Seeman
  • Compositions and methods for alleviating depression or improving cognition
    Patent number: 8791138
    Abstract: This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: July 29, 2014
    Assignee: Clera Inc.
    Inventors: Philip Seeman, Philip M. Tokeikis
  • COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE
    Publication number: 20120115910
    Abstract: This application describes compositions of receptor inhibitors, including typical antipsychotic agents, for example haloperidol, and methods of use for treating clinical signs or symptoms of Parkinson's disease. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in Parkinson's disease as a means of alleviating the clinical signs or symptoms of Parkinson's disease.
    Type: Application
    Filed: July 30, 2010
    Publication date: May 10, 2012
    Applicant: Clera Inc.
    Inventor: Philip Seeman
  • COMPOSITIONS AND METHODS FOR ALLEVIATING DEPRESSION OR IMPROVING COGNITION
    Publication number: 20100298382
    Abstract: This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition.
    Type: Application
    Filed: February 5, 2009
    Publication date: November 25, 2010
    Applicant: CLERA INC.
    Inventors: Philip Seeman, Philip M. Tokeikis
  • SUBSTITUTED BUTYROPHENONE DERIVATIVES
    Publication number: 20100004289
    Abstract: The present invention relates to a central nervous system-acting substituted butyrophenones. These compounds are useful in antipsychotic medications for psychosis, including schizophrenia, but especially for L-DOPA-induced psychosis, while having low or no risk of eliciting extrapyramidal side effects, hyperprolactinemia or tardive dyskinesia.
    Type: Application
    Filed: May 1, 2006
    Publication date: January 7, 2010
    Applicant: CLERA INC.
    Inventor: Philip Seeman
  • METHOD TO DETECT DOPAMINE RECEPTORS IN THE FUNCTIONAL D2HIGH STATE
    Publication number: 20070128107
    Abstract: This application describes a method for identifying dopamine supersensitivity using radioactive (+)PHNO. The method involves determining the specific binding of radioactive (+)PHNO is the subject's brain. An increase in the specific binding of radioactive (+)PHNO in the subject compared to a control indicates that the subject is in a state of dopamine supersensitivity. The extent of dopamine supersensitivity can be used to assess, treat and/or follow the progress of any dopamine-related disorder.
    Type: Application
    Filed: November 10, 2006
    Publication date: June 7, 2007
    Applicant: Clera Inc.
    Inventor: Philip Seeman